Please assess the completion status of the following clinical trial:

Trial Title: Reduced Dose of Unfractionated Heparin in Patients Undergoing PCI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients older than 18 years undergoing a PCI procedure~2. Pretreatment with 600mg clopidogrel at least 2 hours before the intervention~3. Informed, written consent by the patient or her/his legally-authorized representative for participation in the study.~Exclusion Criteria:~1. Recent ST-elevation myocardial infarction within the last 48 hours~2. Acute coronary syndromes with positive biomarkers (Troponin T \> 0.03 μg/L or CK-MB \> ULN)~3. Cardiogenic shock~4. Malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than one year or that may result in protocol non-compliance~5. Active bleeding; bleeding diathesis~6. History of gastrointestinal or genitourinary bleeding within the last 6 weeks~7. Presence of diseases which have a high probability of vascular lesions and subsequent bleeding such as active gastric ulcer or active ulcerous colitis~8. Recent trauma or major surgery in the last month~9. Ophthalmic surgery or brain surgery in the last month~10. Retinopathies or vitreous body bleeding in the last month~11. History of intracranial bleeding or structural abnormalities (for example aneurysm of cerebral arteries)~12. Suspected aortic dissection; pericarditis and subacute bacterial endocarditis~13. Patient's refusal to blood transfusion.~14. Oral anticoagulation therapy with coumarin derivative within the last 7 days~15. Treatment with UFH within 6 hours unless an ACT is less than 150 sec or low-molecular weight heparin within 8 hours before enrollment~16. Treatment with bivalirudin within 24 hours before enrollment~17. Severe uncontrolled hypertension \>180/110 mmHg unresponsive to therapy~18. Planned staged PCI procedure within 30 days from index procedure or prior PCI within the last 30 days.~19. Relevant hematologic deviations: hemoglobin \< 100 g/L, platelet count \< 100 x 109 /L.~20. Glomerular filtration rate (GFR) \< 30 ml/min or serum creatinine \> 30 mg/L or dependence on renal dialysis.~21. Known allergy to the study medications: aspirin, clopidogrel, UFH, true anaphylaxis after prior exposure to contrast media.~22. Known heparin-induced thrombocytopenia (Typ II)~23. Previous enrollment in this trial.~24. Pregnancy (present, suspected or planned) or positive pregnancy test.~25. Spinal, peridural and epidural anesthesia~26. Patient's inability to fully cooperate with the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reduced dose of unfractionated heparin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).